Amwell reports Q4 EPS (17c), consensus (20c)

Reports Q4 revenue $70.7M, consensus $70.2M. We secured and deployed strategic clients who provide us with important validation for our solution. We successfully migrated more than half our volume onto our new platform, Converge, and the ROI proof points are accumulating,” said Ido Schoenberg, MD, chairman and CEO of Amwell. “Finally, we improved efficiency in our company and put in place the important elements to transform our commercial organization to reaccelerate momentum in our business. With the achievements of 2023, we begin 2024 with high conviction regarding our path to profitability.” Reports adjusted EBITDA of ($36.9) M compared to ($38.5) million in the third quarter of 202and Total active providers were 103,000.